FDA Approves New Dosing Guidelines for Afrezza Inhaled Insulin
MannKind (MNKD) receives FDA approval for updated Afrezza dosing recommendations, making it easier for patients to switch from insulin injections to inhaled insulin therapy.
MannKind (MNKD) receives FDA approval for updated Afrezza dosing recommendations, making it easier for patients to switch from insulin injections to inhaled insulin therapy.
Merck has walked away from negotiations to acquire Revolution Medicines after failing to agree on price for the promising cancer drug developer valued around $30 billion.
Apogee Therapeutics stock drops 12% after major investor Fairmount Funds Management sells 1.75 million shares worth $133.5 million, significantly reducing its position.
Leerink starts coverage on Relmada Therapeutics, upgrades the stock to Outperform, and highlights strong potential for its bladder cancer program NDV-01.
Bausch Health said its experimental liver treatment did not meet goals in Phase 3 trials, sending shares lower in early trading.
Oppenheimer initiates coverage of Coherus Oncology with an Outperform rating and a $10 price target, highlighting promising cancer drug programs and key clinical data expected in 2026.